GI Medical Oncologist @CityofHope. Hepatobiliary & NET Cancers
Los Angeles, CA
Joined May 2020
- Tweets215
- Following724
- Followers1.6K
- Likes1.2K
Congrats @AmanChauhanMD on all your hard work and dedication on this IIT. Happy to have been a part of this with you and look forward to many more collaborative efforts to help patients.
Today marks a special milestone-
our first Investigator-Initiated Trial (IIT) publication is now out in Clinical Cancer Research.
IITs are hard. They don’t happen because a protocol gets written—they happen because countless people keep showing up, meeting after meeting, year after year. Looking back over the past five years, I’ve lost track of the number of discussions with our core study team, statisticians, the NCI, participating sites, bioinformatics collaborators, pharmacokinetic laboratory, and many others who made this work possible.
I’ve been fortunate to be involved in many different types of oncology research throughout my career, but seeing the first IIT that I helped design finally published hits differently. There is something uniquely rewarding about taking an idea from concept to lab to protocol, through regulatory hurdles, patient enrollment, data analysis, and finally publication.
Most importantly, thank you to the patients and their families who placed their trust in us. Clinical research moves forward because of your courage.
I am deeply grateful to my mentors, colleagues, collaborators, research staff, and friends who believed in this project and helped carry it across the finish line. This publication belongs to all of you.
Here’s to the next one—and, more importantly, to continuing to ask better questions for our patients.
🔗 pubmed.ncbi.nlm.nih.gov/4251…
@SusanneArnoldMD @LowellAnthonyMD @OncoThor @DanengLi @NANETS1 @CCR_AACR @UKMarkey @UCSF
Daneng Li retweeted
#TumorBoardTuesday
One of the biggest updates at #ASCO26 was on the management of liver only, advanced #HCC
📢Join us Tuesday, 07-21-26 at 8PM ET as @DanengLi & @theGIoncdoc 🗣️the value of EMERALD(s) in HCC?”
RT and bring others into the discussion‼️
Happy to share initial findings of our IIT of Y90+STRIDE in locally advanced #HCC at #ESMOGI26 Feasible and safety consistent with known tox of agents. Prelim ORR of 44% per RECIST consistent with prior TACE+systemic trials. Larger studies underway @cityofhope @COHMedOnc @myESMO
Daneng Li retweeted
Tomorrow: Join us for the Virtual 2026 Neuroendocrine Cancer Patient Conference.
This free online event is designed for people living with neuroendocrine cancer, caregivers, and families seeking trusted, expert-led information.
🗓️ Saturday, June 20
⏲️7:00 AM Pacific
▶️Watch on the NCF website (ncf.net/events/2026conferenc…) or YouTube (youtube.com/watch?v=_GFJYhP0…)
❓ Live Q&A with NET specialists
⏪Pause, rewind, and replay sessions
Hear from 19 leading NET experts, learn about diagnosis, treatment options, imaging, surgery, clinical trials, side effect management, and hear real patient stories.
Submit your questions for the live Q&A through the Slido feed on the event page.
Learn more: NCF.net/events/2026conferenc…
#NeuroendocrineCancer #NETCancer #patienteducation #cancersupport #clinicaltrials #ncfcancer
Daneng Li retweeted
Check out @NANETS1 NETCast #podcast; we focus on 'Beyond the Data: How Physicians Talk to Patients About Uncertainty' with Drs. @DanengLi @COHMedOnc, Dr. John Kunstman @YaleCancer, @TubaKendi @MayoCancerCare & @lisayentwin Director of Programs @NCFCancer podcasts.apple.com/us/podcas…
Daneng Li retweeted
As the sun sets in San Francisco & #GI26 comes to a close, we reflect w/ gratitude on the 3 days we spent w/ all of you in person & online. Three full days of learning & connecting, making progress on treatments and care for patients w/ GI cancers. #gicsm
brnw.ch/21wYZmt
It was wonderful doing this with amazing colleagues @ASCO #GI26. Safe travels to all and look forward to more amazing science later this year @ASCO.
It was wonderful meeting many of our #GI26 Featured Voices in person! A huge ‘thank you’ to ALL of you for lending your time & expertise to help digest symposium findings and provide key takeaways. We couldn’t do it without you!
Daneng Li retweeted
#ASCOGI26 Day 2 ✌️ presenting a meta-analysis on ctDNA as a marker in patients with colorectal cancer with liver metastasis. Thank you for the amazing mentorship from @cityofhope @gagan_brar24 @DaniCastilloMD @montypal
Agree with @jgong15. Good to see studies and investigators doing the right thing and reevaluating continuation of studies when new data becomes available and standards of care changes. Putting patients first is key. @ASCO #GI26
Very interesting findings presented @ASCO #GI26. Could GLP1 have different effects on different GI cancers?Some preclinical data in NETs have shown some possibility of increased risk. Definitely an area of interest to watch out for moving forward.
Promising news from #GI26: Popular weight-loss drugs may have the added benefit of reducing #ColorectalCancer risk.
Learn more: brnw.ch/21wYZ48
#GLP1RA
Daneng Li retweeted
#GI26 Provocative but insightful recommendations on how to select patients for LIVER #Transplant for patients with unresectable liver metastases.
Liver transplant is here to stay. Early selection is of value. But dogmas e.g. no BRAFV600E or N2 need to be challenged.
@OncoAlert
Daneng Li retweeted
Next generation of stellar GI oncologists discussing the impact of ctdna in CRLM #GI26 @ASCO @pshah_88 @DaniCastilloMD @DanengLi @pashtoonkasi @cityofhope
Daneng Li retweeted
Standing room only for this @ASCO #GI26 session on optimizing management of persons with #HCC and decomp #cirrhosis
We spoke about achieving good cancer outcomes with bad livers with co panelists Drs. @BeauToskichMD Stephen Lam Chan and Ana Gleisner.
#livertwitter
Daneng Li retweeted
Great work by one of our surgical colleagues looking at PIN1 expression and PDAC OS. The results may surprise you… @ASCO #GI26 @DanengLi @DaniCastilloMD @gagan_brar24
Daneng Li retweeted
Excellent summary of two important #HCC abstracts at #GI26 by my mentor and colleague Tim Greten @ASCO @DanengLi @DaniCastilloMD
